AZN 250509 69.00P(AZN250509P69000) Stock Price Today | Quotes & News - Moomoo

US OptionsDetailed Quotes

AZN250509P69000

Watchlist

0.49
+0.36+276.92%

15min DelayClose May 6 15:59 ET

0.49High0.20Low

Intraday

5D
Daily

News

Trump Sets Pharma Tariffs Deadline. The Fallout for Lilly, Pfizer, Other Drugmakers
Barron's16:57 ET
AstraZeneca Hits 4-week High
Trading EconomicsMay 6 03:17 ET
AstraZeneca (AZN.US) BTK inhibitor new indication approved by the EU for the treatment of mantle cell lymphoma.
AstraZeneca (AZN.US) announced that acalabrutinib in combination with bendamustine and rituximab has been approved in the European Union for the treatment of adult patients with mantle cell lymphoma (MCL) who have not received prior treatment and are not suitable for autologous stem cell transplantation.
Zhitong FinanceMay 6 02:52 ET
AstraZeneca's Calquence Regimen Wins EU Approval for Mantle Cell Lymphoma
MT NewswiresMay 6 02:39 ET
AstraZeneca's (LON:AZN) Earnings Offer More Than Meets The Eye
Yahoo FinanceMay 6 01:45 ET
India Offers US Reciprocal Zero Tariffs on Steel, Auto Parts, Pharmaceutical Drugs, Bloomberg Reports
MT NewswiresMay 5 10:48 ET

Comments

The World’s ATM

$AstraZeneca (AZN.US)$ should not buy u. all vaccine also banned next time.

1

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy

$AstraZeneca (AZN.US)$
First Major Breakthrough in 10 Years: ENHERTU Combo Outperforms Standard HER2+ Breast Cancer Treatment

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy

ENHERTU® Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Posit

$AstraZeneca (AZN.US)$
First Major Breast Cancer Treatment Breakthrough in 10 Years: ENHERTU Trial Reveals Superior Efficacy

ENHERTU® Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Posit

Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in Collaboration with AstraZeneca

$AstraZeneca (AZN.US)$
Revolutionary AI Technology Detects Lung Cancer Mutations Without Invasive Testing

DATROWAY® Approved in the EU for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

$AstraZeneca (AZN.US)$
New Breast Cancer Drug DATROWAY Shows 37% Better Survival Rates in EU Approval

DATROWAY® Approved in the EU for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

Read more